drugset / Trial / NCT06696183
Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
RandomizedParallel-groupOpen-labelTreatment
Summary
Explore the best tolerable and efficacious dose of Gilteritinib when combined with standard treatment with Venetoclax and Azacitidine in AML patients with FLT3 mutations which are ineligible for intensive chemotherapy
Timeline
- Start
- 2025-04-25
- Primary completion
- 2029-04
- Completion
- 2030-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | — |
| Subject | Gilteritinib | Small molecule | 80 mg | — |
| Subject | Venetoclax | Small molecule | 400 mg | — |